Madison stem cell company, Stemina Biomarker Discovery, is getting a $150,000 Small Business Innovation Research grant from the National Institutes of Health aimed at expanding the use of its drug testing technology for harmful side effects. Co-founded by UW-Madison stem cell researcher Gabriela Cezar, Stemina has been using its technology with heart cells provided by Cellular Dynamics International (CDI), the Madison company founded by UW stem cell pioneer James Thomson, to see if drug compounds could cause cardiomyopathy, a condition that weakens the heart and can lead to heart failure.
Office of Strategic Communication